Occam Recruits Ann Taylor to the Board of Unlearn
Unlearn, an 8VC investment, has developed the first machine learning platform for creating Intelligent Control Arms with Digital Twins, allowing drug developers to dramatically improve clinical evidence and trial power, while lowering the risk of trial failure, thereby increasing confidence in clinical trial results.
In late 2020, Occam recruited Ann Taylor, MD to the Board of Unlearn. Ann brings with her deep experience in clinical development, having served as CMO for AstraZeneca until 2021.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.